Rankiteo Logo
Rankiteo
Leader in Cyber Underwriting
Loading...
NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop
WindowsmacOSLinux
Download

Comparison Overview

Eurofins BioPharma Product Testing ItalyEurofins BioPharma Product Testing Italy
VS
AbbVieAbbVie
Eurofins BioPharma Product Testing Italy

Eurofins BioPharma Product Testing Italy

Via Bruno Buozzi, 2, Vimodrone, (MI), 20090, IT

Last Update: 14/11/2025

View Profile
756/1000Fair

Eurofins Biolab S.r.l. is a GMP & GLP Laboratory part of the BioPharma Product Testing Division of Eurofins Scientific. Pharmaceuticals, Medical Devices, Biocides and Cosmetics are our main areas of interest

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:428
Subsidiaries:49
12-month incidents
0
Known data breaches
0
Attack type number
0
AbbVie

AbbVie

1 Waukegan Road, North Chicago, 60064, US

Last Update: 19/07/2026

View Profile
Between 800 and 849
http://www.abbvie.com
827/1000Good

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, ...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:61,106
Subsidiaries:19
12-month incidents
1
Known data breaches
1
Attack type number
2

Compliance Ranges Comparison

Based On Specific Ai Models Category
Eurofins BioPharma Product Testing Italy

Eurofins BioPharma Product Testing Italy

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA
AbbVie

AbbVie

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Eurofins BioPharma Product Testing Italy in 2026.

Incidents

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

AbbVie has 4.76% fewer incidents than the average of all companies with at least one recorded incident.

Incidents

Incident History - Eurofins BioPharma Product Testing Italy (X = Date, Y = Severity)

Eurofins BioPharma Product Testing Italy cyber incidents detection timeline including parent company and subsidiaries.

No timeline data available
R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Incident History - AbbVie (X = Date, Y = Severity)

AbbVie cyber incidents detection timeline including parent company and subsidiaries.

R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Notable Incidents

Last Cyber / HR Incidents / Global...
Eurofins BioPharma Product Testing Italy

Eurofins BioPharma Product Testing Italy

Incidents
No explicit notable incidents reported.
AbbVie

AbbVie

Incidents
🔒 Incident : Vulnerability
EGAABB1775658772
🔒 Incident : Breach
ABB0473723

FAQ

Between Eurofins BioPharma Product Testing Italy company and AbbVie company, which one has the best AI Cybersecurity Score ?
Between Eurofins BioPharma Product Testing Italy company and AbbVie company, which one has experienced more cyber incidents in the past ?
Between Eurofins BioPharma Product Testing Italy company and AbbVie company, which one has experienced more cyber incidents this year ?
Between Eurofins BioPharma Product Testing Italy company and AbbVie company, which one has experienced at least one ransomware attack ?
Between Eurofins BioPharma Product Testing Italy company and AbbVie company, which one has experienced at least one data breach ?
Between Eurofins BioPharma Product Testing Italy company and AbbVie company, which one has experienced at least one targeted cyberattack ?
Between Eurofins BioPharma Product Testing Italy company and AbbVie company, which one has experienced at least one vulnerability ?
Between Eurofins BioPharma Product Testing Italy company and AbbVie company, which one holds the most compliance certifications ?
Between Eurofins BioPharma Product Testing Italy company and AbbVie company, which one holds the fewest compliance certifications ?
Between Eurofins BioPharma Product Testing Italy company and AbbVie company, which one has the most subsidiaries ?
Between Eurofins BioPharma Product Testing Italy company and AbbVie company, which one has the largest number of employees ?
Between Eurofins BioPharma Product Testing Italy and AbbVie, which company holds both SOC 2 Type 1 certifications ?
Between Eurofins BioPharma Product Testing Italy and AbbVie, which company holds both SOC 2 Type 2 certifications ?
Which company is ISO 27001 certified - Eurofins BioPharma Product Testing Italy or AbbVie ?
Which company is PCI DSS compliant - Eurofins BioPharma Product Testing Italy or AbbVie ?
Between Eurofins BioPharma Product Testing Italy and AbbVie, which company complies with HIPAA regulations for healthcare data ?
Between Eurofins BioPharma Product Testing Italy and AbbVie, which company complies with GDPR requirements ?

Latest Global CVEs

CVE-2026-16197
SUMMARY

A security vulnerability has been detected in Sipeed PicoClaw up to 0.2.9. The affected element is the function handleMessageReceive of the file pkg/channels/feishu/feishu_64.go of the component Group Message Handler. Such manipulation leads to missing authorization. The attack can be launched remotely. The exploit has been disclosed publicly and may be used. The reported GitHub issue was closed automatically due to inactivity.

PUBLISHED
Date2026-07-18
UPDATED
Date2026-07-18
RISK INFORMATION (Score: 6.3)
CVSS2
Base Score: 6.5
Complexity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
CVSS3
Base Score: 6.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
CVSS4
Base Score: 2.1
Complexity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
3.4
EXPLOITABILITY
2.8
CVE-2026-16196
SUMMARY

A weakness has been identified in Sipeed PicoClaw up to 0.2.9. Impacted is the function isPrivateOrRestrictedIP of the file pkg/tools/integration/web.go of the component web_fetch. This manipulation causes server-side request forgery. The attack can be initiated remotely. The exploit has been made available to the public and could be used for attacks. Patch name: 2efbe5d560e7ed9bc5209c203dc4aa6ecdbc7405. To fix this issue, it is recommended to deploy a patch.

PUBLISHED
Date2026-07-18
UPDATED
Date2026-07-18
RISK INFORMATION (Score: 6.3)
CVSS2
Base Score: 6.5
Complexity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
CVSS3
Base Score: 6.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
CVSS4
Base Score: 2.1
Complexity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
3.4
EXPLOITABILITY
2.8
CVE-2026-16195
SUMMARY

A security flaw has been discovered in Sipeed PicoClaw up to 0.2.9. This issue affects the function dispatchIncoming of the file pkg/channels/wecom/wecom.go of the component Group Message Handler. The manipulation results in incorrect authorization. It is possible to launch the attack remotely. The exploit has been released to the public and may be used for attacks. The reported GitHub issue was closed automatically due to inactivity.

PUBLISHED
Date2026-07-18
UPDATED
Date2026-07-18
RISK INFORMATION (Score: 6.3)
CVSS2
Base Score: 6.5
Complexity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
CVSS3
Base Score: 6.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
CVSS4
Base Score: 2.1
Complexity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
3.4
EXPLOITABILITY
2.8
CVE-2026-10130
SUMMARY

QueryWeaver contains an authentication bypass vulnerability that allows unauthenticated attackers to obtain valid session tokens for existing accounts by submitting a signup request with a known victim email address. The signup route unconditionally creates and links a new token to the matching Identity via a Cypher MERGE operation before checking whether the email belongs to an existing account, causing the server to return a valid authenticated session token for the victim's identity without requiring any prior credentials or user interaction.

PUBLISHED
Date2026-07-18
UPDATED
Date2026-07-18
RISK INFORMATION (Score: 8.2)
CVSS3
Base Score: 8.2
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:L/A:N
CVSS4
Base Score: 8.8
Complexity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
4.2
EXPLOITABILITY
3.9
CVE-2026-16194
SUMMARY

A vulnerability was determined in zhayujie CowAgent up to 2.1.1. This affects the function WebFetch.execute of the file agent/tools/web_fetch/web_fetch.py. Executing a manipulation of the argument url can lead to server-side request forgery. The attack may be performed from remote. The exploit has been publicly disclosed and may be utilized. Upgrading to version 2.1.2 is able to mitigate this issue. This patch is called ea47f3097eed4f8295c4cb3d76ecb97e0f43d632. It is recommended to upgrade the affected component. The vendor was contacted early, responded in a very professional manner and quickly released a fixed version of the affected product.

PUBLISHED
Date2026-07-18
UPDATED
Date2026-07-18
RISK INFORMATION (Score: 6.3)
CVSS2
Base Score: 6.5
Complexity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
CVSS3
Base Score: 6.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
CVSS4
Base Score: 2.1
Complexity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
3.4
EXPLOITABILITY
2.8